Outlook Wealth Advisors LLC Increases Holdings in Agilent Technologies, Inc. (NYSE:A)

Outlook Wealth Advisors LLC boosted its position in shares of Agilent Technologies, Inc. (NYSE:A) by 27.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,047 shares of the medical research company’s stock after purchasing an additional 440 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in Agilent Technologies were worth $298,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in A. Norges Bank purchased a new position in Agilent Technologies during the 4th quarter worth $509,904,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Agilent Technologies by 19.6% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 13,246,489 shares of the medical research company’s stock worth $1,841,659,000 after buying an additional 2,170,219 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Agilent Technologies by 939.8% during the third quarter. Victory Capital Management Inc. now owns 2,296,512 shares of the medical research company’s stock worth $256,796,000 after buying an additional 2,075,649 shares during the period. Nordea Investment Management AB increased its position in shares of Agilent Technologies by 233.7% in the 4th quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock valued at $370,552,000 after acquiring an additional 1,867,377 shares during the period. Finally, Brown Advisory Inc. lifted its position in Agilent Technologies by 262.1% during the 4th quarter. Brown Advisory Inc. now owns 2,292,929 shares of the medical research company’s stock worth $318,786,000 after acquiring an additional 1,659,768 shares during the period.

Agilent Technologies Stock Up 1.0 %

Shares of Agilent Technologies stock traded up $1.37 on Friday, reaching $137.74. 754,945 shares of the company were exchanged, compared to its average volume of 1,245,651. The stock’s 50 day moving average price is $141.59 and its 200-day moving average price is $130.56. The company has a market cap of $40.36 billion, a P/E ratio of 32.78, a price-to-earnings-growth ratio of 4.13 and a beta of 1.11. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $151.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04.

Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.22 by $0.07. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. Agilent Technologies’s revenue for the quarter was down 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.37 earnings per share. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.5 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd were paid a $0.236 dividend. The ex-dividend date was Monday, April 1st. This represents a $0.94 annualized dividend and a yield of 0.69%. Agilent Technologies’s dividend payout ratio is presently 22.38%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 52,297 shares of Agilent Technologies stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the transaction, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Michael R. Mcmullen sold 52,297 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares in the company, valued at $38,086,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the transaction, the director now owns 54,976 shares in the company, valued at approximately $7,935,235.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,610 shares of company stock valued at $9,220,333.

Analyst Ratings Changes

Several brokerages have weighed in on A. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and increased their price target for the stock from $145.00 to $163.00 in a research report on Friday, April 5th. Evercore ISI raised their target price on Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Barclays boosted their price target on Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. UBS Group raised their price objective on shares of Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Finally, Citigroup lifted their target price on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $141.29.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.